EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieMultizentrische StudieOpen Access

Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum

T John Winhusen, Michelle R Lofwall, Frankie Kropp, Daniel Lewis, Marcela C Smid, Jessica L Young, Candace Hodgkins, Elizabeth E Krans, Zachary Hansen, Elisha M Wachman, Davida M Schiff, Constance Guille und 9 weitere

JAMA Internal Medicine · 01.05.2026 · 186 (5) · 533

DOI: 10.1001/jamainternmed.2026.0057 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.05.2026. Verfasst von T John Winhusen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Pregnancy Complications, Opiate Substitution Treatment. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treating opioid use disorder (OUD) in pregnancy with sublingual buprenorphine is an evidence-based practice, but it has disadvantages that could be addressed with an extended-release formulation.

Objective

To evaluate the effectiveness and safety of extended-release buprenorphine vs sublingual buprenorphine for OUD in pregnancy through 12 months post partum. Design, Setting, and Participants This 2-group, open-label, noninferiority, randomized clinical trial was conducted between July 2, 2020, and October 30, 2024, among adults with OUD and a singleton pregnancy of 6 to 30 weeks’ gestational age at 13 outpatient cross-disciplinary peripartum OUD treatment sites.

Interventions

Randomization to sublingual or extended-release buprenorphine (weekly formulation during pregnancy, monthly formulation optional post partum if not breastfeeding). Main Outcomes and Measures The primary and key secondary outcomes were illicit opioid abstinence during pregnancy and the postpartum period, respectively, defined as the proportion of weekly collected urine samples negative for illicit opioids. If noninferiority was demonstrated at a margin of 0.15, testing for superiority was planned. Key secondary infant outcomes from medical records were opioid treatment for neonatal opioid withdrawal syndrome (NOWS; yes or no) and number of opioid treatment days for NOWS.

Results

Among 140 randomized participants, the mean (SD) age was 31.2 (4.6) years. There were 10 Black participants (7.1%), 10 Hispanic participants (7.1%), 116 (82.9%) White participants, and 14 participants (10.0%) who belonged to additional groups. All but 2 were already prescribed sublingual buprenorphine. Study completion was 98% through pregnancy (137 participants) and 81% through 12 months post partum (114 participants). Illicit opioid abstinence was higher during pregnancy for participants receiving extended-release vs sublingual buprenorphine (82.5% vs 72.6%; mean difference, 9.84 [95% CI, 1.72 to 17.95] percentage points; P = .009). Postpartum abstinence rates declined and were similar in both groups (60.2% vs 59.5%; mean difference, 0.65 [98% CI, −12.72 to 14.02] percentage points; P = .45). Those receiving extended-release buprenorphine experienced fewer serious adverse events during pregnancy (8.7% vs 26.8%; P = .007) and post partum (6.0% vs 18.6%; P = .04). Nonserious adverse events rates did not differ between groups, but more were deemed medication-related for extended-release participants during pregnancy (26.1% vs 7.0%; P = .003). Infants exposed to extended-release vs sublingual buprenorphine did not differ in need for opioid treatment (30.2% vs 26.5%; relative risk, 1.14 [98% CI, 0.54 to 1.99]; P = .64) or mean (SE) treatment days (10.9 [2.2] vs 14.8 [3.0] days; relative risk, 0.73 [98% CI, 0.36 to 1.51]; P = .28). At birth, extended-release–exposed neonates had larger mean (SE) head circumferences than those exposed to sublingual buprenorphine (34.0 [0.2] vs 33.4 [0.2] cm; mean difference, 0.63 [95% CI, −0.00 to 1.26] cm; P = .049). Conclusions and Relevance The findings of this randomized clinical trial support weekly extended-release buprenorphine for OUD treatment during pregnancy. Trial Registration ClinicalTrials.gov Identifier: NCT03918850

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersPregnancy ComplicationsOpiate Substitution TreatmentNarcotic AntagonistsHumansFemalePregnancyAdministration, SublingualDelayed-Action PreparationsAdultPostpartum Period

Substanzen

BuprenorphineDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • University of Cincinnati/UC Health Addiction Center, Cincinnati, Ohio.
  • Departments of Behavioral Science and Psychiatry, Center on Drug and Alcohol Research, University of Kentucky College of Medicine, Lexington.
  • Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City.
  • Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Gateway Community Services, Jacksonville, Florida.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Winhusen, T. J., Lofwall, M. R., Kropp, F., Lewis, D., Smid, M. C., Young, J. L., Hodgkins, C., Krans, E. E., Hansen, Z., Wachman, E. M., Schiff, D. M., Guille, C., Rudolf, V., Chowdhury, T., Leeman, L., Lewis, M., Matthews, A. G., Cochran, G., King, J., …, & Rosa, C. (2026). Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum. JAMA Internal Medicine, 186(5), 533. https://doi.org/10.1001/jamainternmed.2026.0057

Vancouver

Winhusen TJ, Lofwall MR, Kropp F, Lewis D, Smid MC, Young JL, et al. Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum. JAMA Internal Medicine. 2026;186(5):533. doi:10.1001/jamainternmed.2026.0057

BibTeX
@article{Winhusen2026,
  author = {Winhusen, T John and Lofwall, Michelle R and Kropp, Frankie and Lewis, Daniel and Smid, Marcela C and Young, Jessica L and Hodgkins, Candace and Krans, Elizabeth E and Hansen, Zachary and Wachman, Elisha M and Schiff, Davida M and Guille, Constance and Rudolf, Vania and Chowdhury, Tara and Leeman, Lawrence and Lewis, Mitra and Matthews, Abigail G and Cochran, Gerald and King, Jacquie and Wilder, Christine and Rosa, Carmen},
  title = {Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {5},
  pages = {533},
  doi = {10.1001/jamainternmed.2026.0057}
}
Kostenlos starten →